» Articles » PMID: 31760429

Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis

Abstract

Background: Alterations in mineral metabolism, such as high phosphorus, high parathyroid hormone (PTH), and high fibroblast growth factor-23 (FGF-23) have been identified as potential risk factors for heart failure (HF). Important differences in the prevalence of mineral metabolism abnormalities and in the risk of HF have been reported across race and/or ethnic groups. In this study, we evaluated whether the associations of mineral metabolism markers with HF differed by race and/or ethnicity.

Methods: We included participants free of cardiovascular disease from the Multi-Ethnic Study of Atherosclerosis to quantify rates of HF overall and across race and/or ethnic groups. Using Cox models, we tested associations of baseline higher phosphorus (>4 mg/dL), PTH greater than 65 pg/mL, and FGF-23 greater than 46.5 pg/mL with incident HF, and for interactions by race and/or ethnicity, adjusting for sociodemographic and cardiovascular risk factors.

Results: Among the 6413 participants, median follow-up time was 14.9 years. The incidence rate for HF was highest for African Americans and lowest for Chinese (4.71 and 2.42 per 1000 person-years, respectively). The prevalence of elevated PTH (18.8% vs 7.4%) but not FGF-23 (23.1% vs 28.8%) was higher in African Americans vs Whites. In multivariable models, the associations of elevated PTH (hazard ratio [HR] 1.50, 95% CI: 1.13-1.99) and FGF-23 (HR 1.37, 95% CI: 1.07-1.75) with incident HF were statistically significant. However, the interactions by race and/or ethnicity were not statistically significant.

Conclusions: In a multiethnic population, higher PTH and FGF-23 were associated with risk of HF in African American and Hispanic individuals. There is no evidence that race and/or ethnicity modifies the association of altered mineral metabolism with risk of HF.

Citing Articles

Structural and social determinants of health: The multi-ethnic study of atherosclerosis.

Besser L, Forrester S, Arabadjian M, Bancks M, Culkin M, Hayden K PLoS One. 2024; 19(11):e0313625.

PMID: 39556532 PMC: 11573213. DOI: 10.1371/journal.pone.0313625.


High Serum Phosphate Is Associated with Cardiovascular Mortality and Subclinical Coronary Atherosclerosis: Systematic Review and Meta-Analysis.

Torrijo-Belanche C, Moreno-Franco B, Munoz-Cabrejas A, Calvo-Galiano N, Casasnovas J, Sayon-Orea C Nutrients. 2024; 16(11).

PMID: 38892532 PMC: 11174514. DOI: 10.3390/nu16111599.


Heart failure with preserved ejection fraction in haemodialysis patients: prevalence, diagnosis, risk factors, prognosis.

Yu X, Zhang D, Chen J, Zhang H, Shen Z, Lv S ESC Heart Fail. 2023; 10(5):2816-2825.

PMID: 37394269 PMC: 10567676. DOI: 10.1002/ehf2.14447.


Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population.

Kurpas A, Supel K, Wieczorkiewicz P, Bodalska Duleba J, Zielinska M Biomedicines. 2023; 11(6).

PMID: 37371618 PMC: 10294899. DOI: 10.3390/biomedicines11061523.


Direct and indirect effects of fibroblast growth factor 23 on the heart.

Nakano T, Kishimoto H, Tokumoto M Front Endocrinol (Lausanne). 2023; 14:1059179.

PMID: 36909314 PMC: 9999118. DOI: 10.3389/fendo.2023.1059179.


References
1.
Rubin D . Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1998; 127(8 Pt 2):757-63. DOI: 10.7326/0003-4819-127-8_part_2-199710151-00064. View

2.
White I, Royston P, Wood A . Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011; 30(4):377-99. DOI: 10.1002/sim.4067. View

3.
Gupta A, Kallenbach L, Zasuwa G, Divine G . Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000; 11(2):330-334. DOI: 10.1681/ASN.V112330. View

4.
Schierbeck L, Jensen T, Bang U, Jensen G, Kober L, Jensen J . Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011; 13(6):626-32. DOI: 10.1093/eurjhf/hfr016. View

5.
Scialla J, Parekh R, Eustace J, Astor B, Plantinga L, Jaar B . Race, Mineral Homeostasis and Mortality in Patients with End-Stage Renal Disease on Dialysis. Am J Nephrol. 2015; 42(1):25-34. PMC: 4562864. DOI: 10.1159/000438999. View